Diurnal Group PLC Appointment of Joint Broker (2267X)
20 February 2017 - 6:01PM
UK Regulatory
TIDMDNL
RNS Number : 2267X
Diurnal Group PLC
20 February 2017
20 February 2017
Diurnal Group plc
("Diurnal" or the "Company")
Appointment of Joint Broker
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, today announces the appointment of Panmure Gordon (UK)
Limited to act as the Company's joint broker alongside Numis
Securities Ltd, with immediate effect.
- Ends -
For further information, please visit www.diurnal.co.uk
or contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, CEO
Richard Bungay, CFO
Numis Securities Ltd (Nominated +44 (0)20 7260
Adviser and Joint Broker) 1000
Nominated Adviser: Michael Meade,
Freddie Barnfield, Paul Gillam
Corporate Broking: James Black
Panmure Gordon (UK) Limited (Joint +44 (0) 20
Broker) 7886 2500
Corporate Finance: Freddy Crossley
/ Duncan Monteith
Corporate Broking: Tom Salvesen
+44 (0)20 3727
FTI Consulting 1000
Simon Conway
Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company
developing high quality products for the global market for the
life-long treatment of chronic endocrine conditions, including
Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its
expertise and innovative research activities focus on
circadian-based endocrinology to yield novel product candidates in
the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPLLFVEFRIDLID
(END) Dow Jones Newswires
February 20, 2017 02:01 ET (07:01 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Diurnal Group Plc (London Stock Exchange): 0 recent articles
More Diurnal Grp News Articles